SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories – ABT

May 30th, 2022 17:05 EST

NEW YORK, May 30, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Abbott and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On May 25, 2022, Dr. Robert Califf, the head of the Food and Drug Administration ("FDA"), testified to the Energy and Commerce Subcommittee of the U.S. House of Representatives in connection with the ongoing baby-formula shortage affecting the U.S.  As reported by The New York Times in an article entitled "F.D.A. Chief Details 'Shocking' Conditions at Baby Formula Plant", Dr. Califf "detailed 'egregiously unsanitary' conditions" at the Abbott plant in Michigan that was shut down in February, precipitating the shortage crisis.  Dr. Califf testified that "'the inspection results were shocking'" and that "'[w]e had no confidence in integrity of the quality program at the facility[.]'"   

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

CONTACT:Robert S. WilloughbyPomerantz LLP[email protected]888-476-6529 ext. 7980

SOURCE Pomerantz LLP


You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals